Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations-Reference-Cited by-同舟云学术

Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations

Published:2009-08-30 Issue:5 Volume:36 Page:407-420
ISSN:1567-567X
Container-title:Journal of Pharmacokinetics and Pharmacodynamics
language:en
Short-container-title:J Pharmacokinet Pharmacodyn

Author:

Grimm Hans Peter

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s10928-009-9129-5.pdf

Reference19 articles.

1. Mould D, Sweeney K (2007) The pharmacokinetics and pharmacodynamics of monoclonal antibodies mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 10(1):84–96

2. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28(6):507–532

3. Meno-Tetang GML, Lowe PJ (2005) On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 96(3):182–192

4. Ng CM et al (2005) Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 22(7):1088–1100

5. Ng CM et al (2006) Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 23(1):95–103

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations;PLOS Computational Biology;2024-04-24

2. Pharmacokinetics and toxicity considerations for antibody–drug conjugates: an overview;Bioanalysis;2023-10

3. Strategies for clinical dose optimization of T cell-engaging therapies in oncology;mAbs;2023-02-23

4. A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs;Frontiers in Bioinformatics;2021-09-03

5. Experimental Medicine Study to Measure Immune Checkpoint Receptors PD‐1 and GITR Turnover Rates In Vivo in Humans;Clinical Pharmacology & Therapeutics;2021-02